Abstract
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related death in the United States, with 43,000 deaths per year and a dismal overall 5-year survival rate of only 8%. Early diagnosis and management planning is therefore essential for optimal clinical outcomes in these patients, as survival is largely dependent on cancer stage, with a 5-year survival rate of 29% for localized disease compared with only 3% for metastatic disease. Endoscopic ultrasound (EUS) combined with fine-needle aspiration (FNA) is the most accurate modality available for the diagnosis of pancreatic cancer and has thus resulted in a paradigm shift in the management of these patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call